The Diabetes Update programme is an initiative for trainees in diabetes and endocrinology. It aims to cover the diabetes section of the training curriculum for diabetes and endocrinology issued by the Joint Royal Colleges of Physicians Training Board. It is also a great opportunity for more established clinicians to find out the latest updates in the area of diabetes.
The Diabetes Update programme is an initiative for trainees in diabetes and endocrinology. It aims to cover the diabetes section of the training curriculum for diabetes and endocrinology issued by the Joint Royal Colleges of Physicians Training Board. It is also a great opportunity for more established clinicians to find out the latest updates in the area of diabetes.
REGISTRATION FOR ABCD DIABETES UPDATE 2024 IS NOW CLOSED!
31st January - 2nd February 2024.
The Diabetes Update programme is a new initiative for trainees in diabetes and endocrinology. It aims to cover the diabetes section of the training curriculum for diabetes and endocrinology issued by the Joint Royal Colleges of Physicians Training Board. It is also a great opportunity for more established clinicians to find out the latest updates in the area of diabetes.
ABCD has been working with the In-Patient Diabetes lead for Diabetes UK, Prof Gerry Rayman, and a group of Specialists in Diabetes to produce much needed guidance describing the maintenance and delivery of specialist diabetes services during COVID-19.
The document is intended for those involved in delivering and redesigning diabetes services in the light of this pandemic. It recognises the importance of maintaining certain elements of the diabetes service which will be essential in reducing the burden on hospitals and supporting inpatient teams.
Levemir® insulin, in both its Penfill® and Flexpen® presentations, is to be discontinued, with an anticipated supply end date of December 2026. A Medicine Supply Notification (MSN/2025/036U) has been issued regarding the discontinuation.
In response to this, the Association of British Clinical Diabetologists and the Primary Care Diabetes & Obesity Society have published joint guidance from a multidisciplinary team of healthcare professionals, which aims to support clinicians in appropriately selecting and safely prescribing alternative insulin therapy.
Levemir® insulin, in both its Penfill® and Flexpen® presentations, is to be discontinued, with an anticipated supply end date of December 2026. A Medicine Supply Notification (MSN/2025/036U) has been issued regarding the discontinuation.
In response to this, the Association of British Clinical Diabetologists and the Primary Care Diabetes & Obesity Society have published joint guidance from a multidisciplinary team of healthcare professionals, which aims to support clinicians in appropriately selecting and safely prescribing alternative insulin therapy.
Please note that ABCD reserve the right to amend the programme.
Delegates will rotate around all the workshops:
Workshop A - Diabetic emergencies, Professor Ketan Dhatariya & Dr Omar Mustafa
Workshop B - Foot disease in diabetes, Professor Fran Game & Dr Catherine Gooday
Workshop C - Cardiovascular disease and diabetes, Dr Faizanur Rahman & Dr David Webb
Workshop D - Mental health and diabetes, Dr Hermione Price & Dr Marietta Stadler
This course has been instigated and organised by ABCD. Sponsors have contributed funding towards this event in return for exhibition space. They have had no input into the agenda or the selection of speakers with the exception of any sponsored symposia which are clearly indicated.
At the recent 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago, Illinois, there were three presentations from the ABCD audit programme.
